HomeNewsBusinessEconomyExclusive | Securing vaccines, deal to remove COVID copyrights to top Jaishankar’s talks in US

Exclusive | Securing vaccines, deal to remove COVID copyrights to top Jaishankar’s talks in US

External Affairs Minister S Jaishankar reached the US on Monday for a crucial five-day visit. This is the first official trip by a foreign minister from either side, after the Biden administration took charge.

May 24, 2021 / 17:09 IST
Story continues below Advertisement
External Affairs Minister S Jaishankar (Representative image)
External Affairs Minister S Jaishankar (Representative image)

Vaccine distribution, be it in the form of bilateral assistance or through a global deal to temporarily remove intellectual property rights waivers for pharma companies, will top the agenda as External Affairs Minister S Jaishankar holds discussions in Washington DC with his American counterpart Secretary of State Antony Blinken later this week.

As of mid-May, the US had more than 27 million unused Moderna vaccine doses and 35 million doses from Pfizer Inc and BioNTech SE, according to data compiled by the Centers for Disease Control and Prevention.

Story continues below Advertisement

“This so-called stockpile is expected to continue to grow in the immediate future as the pace of vaccination in the US falls with large percentage of critical age groups having already been inoculated," a senior official said.

While the US had, last month, said it will donate up to 80 million doses of the AstraZeneca jab, it has not clarified which countries will make the cut and how much will be allocated to each. On the other hand, the deadline has been made murky by the fact that the US Centres for Disease Control (CDC) is yet to officially approve the use of the AstraZeneca doses.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show